171 related articles for article (PubMed ID: 31235042)
1. Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.
Grolleau E; Haddad V; Boissière L; Falchero L; Arpin D
J Thorac Oncol; 2019 Jul; 14(7):e151-e153. PubMed ID: 31235042
[No Abstract] [Full Text] [Related]
2. Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.
Schmid S; Stewart EL; Martins-Filho SN; Cabanero M; Wang A; Bao H; Wu X; Patel D; Chen Z; Law JH; Bradbury PA; Shepherd FA; Leighl N; Tsao MS; Pugh T; Bratman SV; Sacher A; Liu G
Clin Lung Cancer; 2020 Sep; 21(5):e488-e492. PubMed ID: 32389504
[No Abstract] [Full Text] [Related]
3. Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report.
Zhang YJ; Li H; Zhong R; Chen W; Kou G; Liu G; Cheng Y
Clin Lung Cancer; 2020 Sep; 21(5):e493-e496. PubMed ID: 32418825
[No Abstract] [Full Text] [Related]
4. Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.
Yang X; Huang C; Chen R; Zhao J
Clin Lung Cancer; 2020 Jul; 21(4):e258-e260. PubMed ID: 32146032
[No Abstract] [Full Text] [Related]
5. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
[TBL] [Abstract][Full Text] [Related]
6. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
[TBL] [Abstract][Full Text] [Related]
7. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.
Chiang CL; Yeh YC; Chou TY; Chiu CH
J Formos Med Assoc; 2020 Sep; 119(9):1439-1441. PubMed ID: 32173232
[No Abstract] [Full Text] [Related]
8. Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.
Piotrowska Z; Fintelmann FJ; Sequist LV; Jahagirdar B
J Thorac Oncol; 2018 Oct; 13(10):e204-e206. PubMed ID: 30244855
[No Abstract] [Full Text] [Related]
9. Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.
Lu H; Dowell J
In Vivo; 2020; 34(1):315-319. PubMed ID: 31882494
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
11. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
Okuno T; Arakawa S; Yoshida T; Ohe Y
Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
[No Abstract] [Full Text] [Related]
13. Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.
Knetki-Wróblewska M; Kowalski DM; Czyżewicz G; Bryl M; Wrona A; Dziadziuszko R; Kieszko R; Milanowski J; Świniuch D; Ramlau R; Krzakowski M
Adv Respir Med; 2020; 88(3):189-196. PubMed ID: 32706102
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
15. Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.
Kunimasa K; Nishino K; Kukita Y; Matsumoto S; Kawachi H; Kawamura T; Inoue T; Tamiya M; Honma K; Sugimoto N; Yamasaki T; Imamura F; Goto K; Kumagai T
Cancer Genet; 2021 Aug; 256-257():57-61. PubMed ID: 33901930
[TBL] [Abstract][Full Text] [Related]
16. Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
Xie Z; Gu Y; Xie X; Lin X; Ouyang M; Qin Y; Zhang J; Lizaso A; Chen S; Zhou C
Clin Lung Cancer; 2021 May; 22(3):e390-e394. PubMed ID: 32693944
[No Abstract] [Full Text] [Related]
17. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
Lee K; Kim D; Yoon S; Lee DH; Kim SW
Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
[TBL] [Abstract][Full Text] [Related]
18. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.
Fang YF; Liu PC
Thorac Cancer; 2021 Dec; 12(24):3429-3432. PubMed ID: 34729927
[TBL] [Abstract][Full Text] [Related]
19. Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response
Foggetti G; Li C; Cai H; Hellyer JA; Lin WY; Ayeni D; Hastings K; Choi J; Wurtz A; Andrejka L; Maghini DG; Rashleigh N; Levy S; Homer R; Gettinger SN; Diehn M; Wakelee HA; Petrov DA; Winslow MM; Politi K
Cancer Discov; 2021 Jul; 11(7):1736-1753. PubMed ID: 33707235
[TBL] [Abstract][Full Text] [Related]
20. Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report.
Bie Y; Wang J; Xiong L; Wang D; Liao J; Zhang Y; Lin H
Medicine (Baltimore); 2021 Mar; 100(11):e24793. PubMed ID: 33725945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
